| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Charles Robert Evans last filed a Form 4 in October 2020, as Director at MDXG. Charles Robert Evans's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 121,357 shares of MDXG. Net of sales, the MDXG filings show accumulation of 10,000 shares.
Charles Robert Evans has 6 Form 4 filings on record from May 2015 to October 2020, all as Director at Mimedx Group (MDXG), 2015–2020.
The 6 reported transactions were 5 stock awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $78K and no sales.
The only open-market purchase was 10,000 shares of MDXG at an average $7.84 on November 13, 2015, about $78K.
Shares as reported in the last Form 4 for each company; the most recent is from October 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 13, 2015 | MDXG Mimedx Group, Inc. | Director | Buy | 10,000 | $7.84 | $78,387.00 | +45.7% |